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Background: Environmental biomonitoring data provide one way to examine race/ethnicity and income-related
exposure disparity and identify potential environmental justice concerns.
Methods: We screened U.S. National Health and Nutrition Examination Survey (NHANES) 2001–2008
biomonitoring data for 228 chemicals for race/ethnicity and income-related disparity. We defined six subgroups by
race/ethnicity—Mexican American, non-Hispanic black, non-Hispanic white—and income—Low Income: poverty
income ratio (PIR) <2, High Income: PIR≥ 2. We assessed disparity by comparing the central tendency (geometric mean
[GM]) of the biomonitoring concentrations of each subgroup to that of the reference subgroup (non-Hispanic white/
High Income), adjusting for multiple comparisons using the Holm-Bonferroni procedure.
Results: There were sufficient data to estimate at least one geometric mean ratio (GMR) for 108 chemicals; 37 had at least
one GMR statistically different from one. There was evidence of potential environmental justice concern (GMR significantly
>1) for 12 chemicals: cotinine; antimony; lead; thallium; 2,4- and 2,5-dichlorophenol; p,p’-dichlorodiphenyldichloroethylene;
methyl and propyl paraben; and mono-ethyl, mono-isobutyl, and mono-n-butyl phthalate. There was also evidence
of GMR significantly <1 for 25 chemicals (of which 17 were polychlorinated biphenyls).
Conclusions: Although many of our results were consistent with the U.S. literature, findings relevant to environmental
justice were novel for dichlorophenols and some metals.
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Environmental justice (EJ) concerns can arise when racial/
ethnic minorities or those with lower socioeconomic sta-
tus (SES) experience greater exposures to environmental
pollutants than the rest of the population. Demographic
variables used to characterize SES can include income,
education, or occupation. Many EJ studies have focused
on disparities in exposure to ambient air pollutant levels.
Studies on hazardous air pollutants have found higher
cancer risks associated with lower SES, higher proportion
of African Americans, and lower proportion of whites in a
census tract [1]; higher level of racial segregation [2]; and
higher proportion of Hispanics [3]. U.S. counties with the* Correspondence: Anna_Belova@abtassoc.com
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reproduction in any medium, provided the orhighest fine particulate matter (PM2.5) and ozone levels
had higher percentages of people living in poverty and
non-Hispanic black residents [4], and Hispanics and non-
Hispanic blacks had higher exposures to PM2.5 compo-
nents than whites [5].
Environmental biomonitoring—assessing exposure to
pollutants/chemicals by measuring them or their metab-
olites in blood, urine, or other specimens—provides a
complementary approach to examining potential dispar-
ities and identifying EJ concerns. Biomonitoring concen-
trations (i.e., biomarkers) reflect the amount of chemical
entering the body from all sources (air, water, food,
soil, dust, consumer products) via all exposure routes
(ingestion, inhalation, dermal absorption) [6]. One chem-
ical may be assessed in the body using several biomarkers
(e.g., lead in blood and urine). Biomarkers are particu-
larly informative when source- and route-specific data areLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Belova et al. Environmental Health 2013, 12:114 Page 2 of 17
http://www.ehjournal.net/content/12/1/114limited. However, detailed studies are required to link bio-
marker concentrations back to environmental exposures
for policy-setting purposes. Biomarkers also reflect how a
given individual absorbs, distributes, metabolizes, and ex-
cretes the chemical (i.e., toxicokinetics), all of which may
be influenced by genetic and epigenetic characteristics that
could vary by race/ethnicity or SES [7,8]. Furthermore, the
presence of an environmental chemical in an individual’s
blood or urine does not imply that this chemical causes
disease [6].
To date, most detailed studies of race/ethnicity or
income-related disparities using biomarker data have
been hypothesis-driven, focusing on a few chemicals se-
lected based on known or suspected exposure disparities
and controlling for relevant covariates. This approach
may miss important disparities in exposure to less stud-
ied chemicals. A screening-level analysis of a large num-
ber of biomarkers for differential exposure could identify
additional candidates for detailed study of the potential
magnitude, drivers, and public health relevance of any
race/ethnicity or income-related disparities.
The U.S. Centers for Disease Control and Prevention
(CDC) collects and tracks environmental biomonitoring
data through the National Health and Nutrition Examin-
ation Survey (NHANES). The Fourth National Report on
Human Exposure to Environmental Chemicals [6] exam-
ines concentrations of 212 chemicals in NHANES 1999–
2004, providing means and select percentiles stratified
by survey years, age group, sex, and race/ethnicity.
(Tables were recently updated for 117 chemicals, and they
incorporate 34 new chemicals from NHANES 2005–2010
[9].) However, the report does not statistically compare
biomarkers across racial/ethnic subgroups, or consider in-
come, an important EJ dimension.
One example of an exploratory assessment for a large
number of chemicals is a recent study by Tyrrell et al.
that investigated associations between income and levels
of 179 chemicals in NHANES 2001–2010 [10]. The
authors used linear regression modeling to test for sig-
nificant associations between the poverty income ratio
(PIR) and log-transformed biomarker concentrations, con-
trolling for age, sex, race, and waist circumference. For
chemicals with significant negative PIR associations in at
least two NHANES cycles, Tyrrell et al. used structural
equation modeling to explore the pathways through which
income impacts the biomarker concentrations. However,
Tyrrell et al. did not use a formal procedure to adjust for
multiple testing, implying that some of their significant
findings could be spurious.
To demonstrate a formal screening method, we ana-
lyzed all biomarkers in the NHANES 2001–2008 datasets
for differences in concentration across U.S. population
subgroups defined by race/ethnicity and income. We
build upon the Fourth Exposure Report and on Tyrrellet al. [10] by: (1) modeling joint impacts of race/ethnicity
and income; (2) testing for statistically significant evi-
dence of disparity with proper adjustments for multiple
comparisons; and (3) addressing measurements below the
limit of detection (LOD) using variable-threshold censored
regression. This screening method focuses on differences
in mean biomarker concentrations among subgroups.
Methods
Data
NHANES collects nationally representative environmen-
tal biomonitoring data from approximately 2,500 partici-
pants in each two-year cycle [6]. Ethical approval for use
of NHANES data that is freely available on the web is
not required as it is anonymized. We analyzed data from
19 of the most recently available (as of May 2011)
NHANES laboratory and demographic files, corre-
sponding to 2001–2002 (1 chemical), 2003–2004 (162
chemicals), and 2007–2008 (65 chemicals) [11-14]. We
aggregated chemicals into 10 groups: cotinine, haloge-
nated aromatics, metals, polycyclic aromatic hydrocarbons
(PAHs), polyfluoralkyl chemicals (PFCs), perchlorate, pes-
ticides, phenols, phthalates, and volatile organic com-
pounds (VOCs) [see Table A1 in Additional file 1]. Each
chemical could be measured in different media and/or
using different corrections; we defined these different
measures as separate biomarkers. For example, the chem-
ical lead (Pb) was measured in blood and urine, reported
as both unadjusted and creatinine-corrected. Thus, there
were three biomarkers associated with the chemical Pb.
We analyzed a total of 410 biomarkers corresponding to
228 chemicals. We parallel the presentation of units in the
Fourth Exposure Report [6]. We present urinary concen-
trations per volume of urine and per gram of creatinine.
While creatinine correction should account for urine dilu-
tion in spot urine samples, creatinine levels can vary by
age, sex, race, renal function, lean muscle mass, and red
meat consumption [15]. Lipophilic chemicals (such as di-
oxins, furans, and polychlorinated biphenyls [PCBs]) are
presented per gram of total lipid (reflecting the amount
stored in body fat) as well as per whole weight of serum.
Other chemicals measured in serum are presented per
liter of serum. For each biomarker, we calculated the LOD
by multiplying reported concentrations by √2 for observa-
tions flagged “below LOD.”
We computed the relevant summary measures for
Mexican American, non-Hispanic black, and non-Hispanic
white race/ethnicity categories available in NHANES, but
not the other Hispanic or “other race” categories because
their small sample sizes do not permit generating reliable
estimates [16] and because of potential heterogeneity of ex-
posure patterns in these subpopulations [17]. To categorize
participants by income, we used the PIR reported by
NHANES. PIR is a family’s total income divided by the
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published in the Federal Register by the U.S. Department
of Health and Human Services. While some NHANES
studies used a three-way PIR-based classification, e.g., poor
(PIR < 1), near poor (1 ≤ PIR < 2), and not poor (PIR ≥ 2)
[18,19], we found that a three-way PIR-based catego-
rization often results in small subgroup sample sizes when
combined with a three-way race/ethnicity-based catego-
rization. Instead, we employed a pseudo-balanced two-way
categorization (since the unweighted median PIR in our
dataset was close to 2), defining “Low” Income (PIR < 2)
and “High” Income (PIR ≥ 2) subgroups. A PIR threshold
of 2 is used by some U.S. agencies as a qualifier for govern-
ment assistance [20] and was also used to explore Vitamin
D deficiency using NHANES data [21].
Thus, we classified individuals into six race/ethnicity
and income subgroups, with non-Hispanic white/High
Income serving as the reference subgroup. For each bio-
marker, we analyzed data for all participants with non-
missing biomarker measurements and PIR. There were
no individuals with missing race/ethnicity status in the
NHANES datasets we examined. Depending on the bio-
marker, the final analytic sample included between 90%
and 95% of all participants with non-missing biomarker
measurements.
Analysis
Following CDC [6], we assumed that biomarker concen-
trations could be treated as lognormally distributed, and
used the geometric mean (GM) as the measure of cen-
tral tendency. Biomarker concentrations were censored
by the LOD, which could be individual-specific for some
biomarkers. While replacement of concentrations below
the LOD by LOD/√2 has been employed [6], this type of
substitution has been shown to generate biased estimates
[22,23]. In our analysis, we accommodated the LOD cen-
soring by estimating variable-threshold censored regression
models [22,24].
Specifically, for each biomarker b we evaluated the




















where cbi is the concentration of biomarker b measured
in the ith individual, LODbi is the LOD for that bio-
marker for the ith individual; wbi is the individual-
specific survey weight; Φ(.) is the cumulative standard
normal distribution and ϕ(.) is the standard normal dis-
tribution; and μbi and σbi are the arithmetic mean and
the arithmetic standard deviation of ln cbi for the ithindividual, respectively. We constrained μbi (and σbi) to
be the same for participants in the same subgroup s, per-
mitting estimation of subgroup-specific GMs and geo-
metric standard deviations (GSDs). In other words, we
sought to maximize the pseudo-log-likelihood function
in equation (1) under simple linear equality constraints.
If μ^bs and σ^ bs denote the estimates of μbs and σbs for bio-
marker b in subgroup s, then the estimated GM and
GSD for this biomarker in this subgroup are exp μ^bsð Þ
and exp σ^ bsð Þ; respectively.
We followed CDC’s convention of not reporting GM
estimates for subsamples with >40% of results below the
LOD [6]. We estimated sampling variances of parame-
ters in the constrained version of the model in equation
(1) using the Taylor series method [25], which relies on
results in Binder [26]. Methods described in [27] were
used to generate point and range estimates for sub-
populations of interest. Specifically, to accommodate
the complex design and laboratory subsample weights
in our subpopulation analysis, we employed Stata/SE
11.2 [28,29] < svy, subpop(if …): intreg > programming
statements. When laboratory weights were not provided,
we followed CDC/NCHS [25] and used the two-year
examination weights. Weighted NHANES estimates are
representative of the U.S. civilian, non-institutionalized
population.
Testing for disparity
We assessed potential race/ethnicity and income-related
disparity at the center of each biomarker distribution
using the following metric:
GMRbs ¼ GMbsGMbr ; ð2Þ
where GMRbs is the ratio of the GM of biomarker b in
subgroup s (GMbs) with respect to the GM of biomarker
b in the reference subgroup r (GMbr). Non-Hispanic
white/High Income was the reference subgroup. Up to five
GM comparisons could be made for each biomarker.
A particular subgroup-specific GMbs is not different
from the reference subgroup GMbr when GMRbs = 1. For
each biomarker b and subgroup s, we tested the null hy-
pothesis that GMRbs = 1 using two-sided tests because
we had no a priori beliefs about directionality.
Because GMR involves a non-linear transformation of
equation (1) parameters, whose estimators are t-distributed,
the sampling distribution of the GMR estimator
exp μ^bs−μ^brð Þ is not known. Therefore, the tests were
carried out in the log-space, by evaluating the hypothesis
μbs − μbr = 0 rather than GMRbs = 1. Along with esti-
mates μ^bs and μ^br , Stata/SE 11.2 reports survey design-
adjusted estimates of the relevant variances— V^ μbsð Þ ,
V^ μbrð Þ —and covariances— C^ μbs; μbrð Þ . Under the
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μ^bs−μ^brð Þ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
V^ μbsð Þ þ V^ μbrð Þ−2C^ μbs; μbrð Þ
q
is a central
t-distribution with degrees of freedom determined by
the NHANES survey design features. This distribution
was used to derive p-values for each test. The confidence
intervals for the GMRs were obtained by exponentiating
the confidence intervals for μbs − μbr.
Our screening analysis involved multiple testing of the
hypothesis GMRbs = 1 for several subgroup-specific GMRs
and a large number of biomarkers. A large number of false
positives is expected with this many comparisons. There-
fore, we capped the probability of encountering at least
one false positive among all tests at 0.05 using the Holm-
Bonferroni procedure [30]. That is, we controlled the
family-wise error rate (FWER) at 5%, where the family of
tests was the entire collection of comparisons. This
allowed us to summarize the screening results for all bio-
markers and subgroups together [31]. This approach
follows best practices in biomedical research and conforms
to the guidelines of the U.S. Food and Drug Administration,
which recommends controlling the FWER in clinical trials
[32]. Last, we qualitatively validated our statistically signifi-
cant results by reviewing the published literature on those
biomarkers for evidence of disparity.
Results
Although we examined 228 chemicals, there were only
108 chemicals for which at least one GMR could be
estimated. Among the 795 GM comparisons across
subgroups and biomarkers, there were 37 chemicals with
significant evidence of disparity: 12 chemicals with at
least one GMR significantly >1, indicating potential EJ
concerns, and 25 chemicals with at least one GMR sig-
nificantly <1, indicating higher exposures in the refer-
ence subgroup (non-Hispanic white/High Income).
Additional information on the overall GMR screening
results at the comparison, biomarker, and chemical level
is provided in Table A2 [see Additional file 1].
Figure 1 provides a visual overview of the results. A
few broad patterns can be discerned. First, the pre-
dominance of grey indicates that many GMRs could
not be calculated because of the large number of non-
detectable concentrations. Second, the relatively small
number of red and blue cells indicates that the GM
concentrations in the subgroups were rarely signifi-
cantly different from those of the reference subgroup
for the biomarkers with computable GMRs. This
could be due to the fact that the differences were not
large or there was insufficient power to detect these differ-
ences. Third, there were instances where Mexican
Americans, particularly low income, had significantly
lower levels of biomarkers than the reference subgroup.
Fourth, biomarker levels for low-income, non-Hispanic whites were generally similar to those for
high-income, non-Hispanic whites (the reference sub-
group). Finally, evidence of significant EJ disparity is
generally seen in non-Hispanic blacks (low and high in-
come) and low-income Mexican Americans.
Examining results at the chemical level, additional
observations can be made. Pesticides, phthalates, and
cotinine contained biomarkers for which all GMRs
significantly different from one were also >1, indicating
potential EJ concern. Conversely, halogenated aromatics
(PCBs in this case), PFCs, and perchlorate included bio-
markers for which GMRs significantly different from
one were exclusively <1, indicating higher exposures in
the reference subgroup. Mixed results (GMRs both
significantly >1 and <1) were encountered among phe-
nols and metals. No evidence of significant disparity was
found for PAHs or VOCs. However, a large fraction of
GMRs could not be estimated for VOCs, pesticides, or
halogenated aromatics.
Table 1 presents information on the 12 chemicals cor-
responding to 31 GMRs significantly >1, indicating po-
tential EJ concerns for the following chemical groups:
cotinine, metals, pesticides, phenols, and phthalates. Of
the 31 GMRs >1, there were 14 for the non-Hispanic
black/Low Income, 10 for the non-Hispanic black/High
Income, 5 for the Mexican American/Low Income, 1 for
the Mexican American/High Income, and 1 for the non-
Hispanic white/Low Income subgroups. Sample sizes
were consistently smallest for the Mexican American/
High Income subgroup. The GMRs in Table 1 range
from 1.3 to 12, but should not be compared across bio-
markers except with great caution because of the differ-
ences in variability of the concentration levels across
biomarkers.
Table 2 presents information on the 25 chemicals cor-
responding to 55 GMRs significantly <1, indicating
higher GMs in the non-Hispanic white/High Income
reference subgroup. PCBs accounted for 17 of these
25. Of the 55 GMRs <1, most (41 PCB congeners) were
among the halogenated aromatics, with others found
among metals (7), perchlorate (2), PFCs (3), and phenols
(2). For PCBs, many instances of GMR < 1 occurred for the
Mexican American/Low Income subgroup.
Of the 12 chemicals our screening method identified
as having higher concentrations in low-income or mi-
nority groups (Table 1), we found published evidence of
EJ concern for cotinine, lead, p,p’-dichlorodiphenyldichlor-
oethylene (DDE), methyl and propyl paraben, phthalates,
and antimony (Sb), and no published evidence for thallium
(Tl) or dichlorophenols.
Cotinine
We found income-related disparity in cotinine and other
tobacco smoke biomarkers (e.g., Pb and Sb). There is an
Figure 1 Visual overview of GMR for NHANES environmental biomonitoring data for all subgroups. Each cell of the matrix summarizes
the outcome of the geometric mean ratio (GMR) test performed. The key to the color codes is located under the matrix. The columns correspond
to the five race/ethnicity subgroups (Mexican American/High Income; Mexican American/Low Income; non-Hispanic black/High Income; non-Hispanic
black/Low Income; non-Hispanic white/Low Income) that are being compared to the reference subgroup (non-Hispanic white/High Income). The rows
of the matrix correspond to 410 studied biomarkers. The chemical groups to which these biomarkers belong (cotinine; halogenated aromatics; metals;
polycyclic aromatic hydrocarbons, PAHs; polyfluoralkyl chemicals, PFCs; perchlorate; pesticides; phenols; phthalates; volatile organic compounds, VOCs)
are indicated along the right edge of the matrix.
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income U.S. subpopulations [33].
Lead
We found significantly higher blood and urine Pb among
low-income, non-Hispanic blacks, despite the fact that
blood and urine Pb have been found to be weakly corre-
lated and that blood Pb is considered a more reliable bio-
marker than urine Pb [34,35]. Our finding agrees withPirkle et al. [36], who found the covariates non-Hispanic
black race and low income to be significantly positively as-
sociated with blood Pb across all age groups in a multiple
regression analysis, using NHANES 1991–1994 data,
and with results reported in Tyrrell et al. [10].
DDE
We found elevated serum p,p’-DDE—a ubiquitous, neuro-
toxic dichlorodiphenyltrichloroethane (DDT) metabolite—
Table 1 Chemicals demonstrating EJ concern (GMR > 1 at 5% joint significance level)
Chemical group
(NHANES cycle)a











ratio (95% CI)dRace/Ethnicity Income
Cotinine (2007–2008) COTININE (ng/mL, serum) NHB Low 787 (43) 1.7 (1.2–2.3) 1,752 (390) 0.14 (0.074–0.25) 12 (6.1–25)
COTININE (ng/mL, serum) NHW Low 1,342 (104) 1.3 (0.67–2.4) 1,752 (390) 0.14 (0.074–0.25) 9.4 (6.5–13)
Metals (2007–2008) ANTIMONY (ug/L, urine) NHB High 284 (30) 0.082 (0.076–0.089) 581 (154) 0.052 (0.046–0.059) 1.6 (1.4–1.8)
ANTIMONY (ug/L, urine) NHB Low 264 (19) 0.088 (0.078–0.098) 581 (154) 0.052 (0.046–0.059) 1.7 (1.4–2.0)
LEAD (ug/dL, blood) NHB Low 872 (0) 1.5 (1.4–1.7) 1,819 (0) 1.2 (1.1–1.3) 1.3 (1.2–1.4)
LEAD (ug/L, urine) NHB Low 264 (1) 0.67 (0.62–0.72) 581 (19) 0.43 (0.40–0.47) 1.6 (1.4–1.7)
THALLIUM (ug/L, urine) NHB High 284 (1) 0.18 (0.17–0.2) 581 (5) 0.14 (0.13–0.15) 1.3 (1.2–1.4)
Pesticides (2003–2004,
2007–2008)
2,4-DICHLOROPHENOL (ug/L, urine) NHB High 258 (10) 1.8 (1.4–2.2) 588 (65) 0.79 (0.69–0.89) 2.3 (1.7–2.9)
2,4-DICHLOROPHENOL (ug/L, urine) NHB Low 297 (14) 1.7 (1.4–2.2) 588 (65) 0.79 (0.69–0.89) 2.2 (1.8–2.8)
2,4-DICHLOROPHENOL
(ug/g, urine, creatinine-adj.)
NHB Low 297 (14) 1.4 (1.1–1.7) 588 (65) 0.81 (0.72–0.91) 1.8 (1.4–2.2)
2,5-DICHLOROPHENOL (ug/L, urine) NHB High 258 (0) 28 (21–38) 588 (11) 6.0 (4.7–7.6) 4.7 (3.2–7.0)
2,5-DICHLOROPHENOL
(ug/g, urine, creatinine-adj.)
NHB High 258 (0) 21 (15–28) 588 (11) 6.3 (4.9–8.0) 3.3 (2.3–4.8)
2,5-DICHLOROPHENOL (ug/L, urine) NHB Low 297 (2) 28 (19–41) 588 (11) 6.0 (4.7–7.6) 4.7 (3.3–6.5)
2,5-DICHLOROPHENOL
(ug/g, urine, creatinine-adj.)
NHB Low 297 (2) 23 (16–33) 588 (11) 6.3 (4.9–8.0) 3.7 (2.6–5.2)
P,P’-DDE (ng/g, serum, lipid-adj.) MA High 127 (0) 420 (320–570) 524 (1) 210 (170–250) 2.1 (1.6–2.7)
P,P’-DDE (ng/g, serum) MA Low 312 (0) 2.7 (2.2-3.4) 524 (1) 1.3 (1.0-1.6) 2.1 (1.6–2.8)
P,P’-DDE (ng/g, serum, lipid-adj.) MA Low 312 (0) 450 (360–560) 524 (1) 210 (170–250) 2.2 (1.7–2.8)
Phenols (2007–2008) METHYL PARABEN (ng/mL, urine) NHB High 258 (0) 170 (150–200) 588 (1) 51 (41–64) 3.3 (2.6–4.2)
METHYL PARABEN
(ng/g, urine, creatinine-adj.)
NHB High 258 (0) 130 (110–150) 588 (1) 54 (42–69) 2.3 (1.7–3.1)
METHYL PARABEN (ng/mL, urine) NHB Low 297 (1) 140 (110–180) 588 (1) 51 (41–64) 2.7 (1.9–3.9)





MA Low 306 (0) 180 (160–220) 588 (0) 120 (100–140) 1.5 (1.3–1.8)
MONO-ETHYL PHTHALATE
(ng/mL, urine)
NHB High 258 (0) 280 (230–330) 588 (0) 120 (100–140) 2.3 (1.8–2.8)
MONO-ETHYL PHTHALATE
(ng/g, urine, creatinine-adj.)
NHB High 258 (0) 200 (170–250) 588 (0) 130 (110–140) 1.6 (1.3–1.9)
MONO-ETHYL PHTHALATE
(ng/mL, urine)
NHB Low 297 (0) 240 (210–280) 588 (0) 120 (100–140) 2.0 (1.6–2.5)
MONO-ETHYL PHTHALATE
(ng/g, urine, creatinine-adj.)















Table 1 Chemicals demonstrating EJ concern (GMR > 1 at 5% joint significance level) (Continued)
MONO-ISOBUTYL PHTHALATE
(ng/mL, urine)
MA Low 306 (1) 10 (8.8–12) 588 (20) 6.0 (5.5–6.6) 1.7 (1.4–2.0)
MONO-ISOBUTYL PHTHALATE
(ng/g, urine, creatinine-adj.)
MA Low 306 (1) 10 (8.5–12) 588 (20) 6.3 (5.8–6.8) 1.6 (1.3–1.9)
MONO-ISOBUTYL PHTHALATE
(ng/mL, urine)
NHB Low 297 (1) 11 (10–12) 588 (20) 6.0 (5.5–6.6) 1.9 (1.6–2.1)
MONO-ISOBUTYL PHTHALATE
(ng/g, urine, creatinine-adj.)
NHB Low 297 (1) 9.2 (8.5–9.9) 588 (20) 6.3 (5.8–6.8) 1.5 (1.3–1.6)
MONO-N-BUTYL PHTHALATE
(ng/mL, urine)
NHB Low 297 (2) 27 (24–30) 588 (10) 16 (15–19) 1.6 (1.4–2.0)
Notes: (a) Biomarkers were assigned to chemical groups on the basis of chemical consistency and groupings from the NHANES laboratory files. Biomonitoring data for the results in the table come from NHANES 2007–2008 for all
chemical groups except pesticides, for which some of the data also come from NHANES 2003–2004. (b) MA – Mexican American, NHB – non-Hispanic black, NHW – non-Hispanic white; Low income corresponds to family PIR < 2,
High income corresponds to family PIR ≥ 2 (PIR is the poverty income ratio). (c) The number of observations is unweighted. The number of non-detects (ND) is reported in parentheses. (d) The point estimate, followed by the range
















Table 2 Chemicals with higher biomarker levels in the reference subgroup (GMR < 1 at 5% joint significance level)
Chemical group
(NHANES cycle)a











ratio (95% CI)dRace/Ethnicity Income
Halogenated aromatics
(2003–2004)
PCB74 (ng/g, serum) MA High 128 (0) 0.019 (0.016–0.023) 519 (0) 0.032 (0.03–0.035) 0.58 (0.48–0.72)
PCB74 (ng/g, serum, lipid-adj.) MA High 128 (0) 3.0 (2.6–3.4) 519 (0) 5.3 (4.9–5.7) 0.57 (0.49–0.66)
PCB74 (ng/g, serum) MA Low 276 (0) 0.013 (0.011–0.015) 519 (0) 0.032 (0.03–0.035) 0.40 (0.33–0.48)
PCB74 (ng/g, serum, lipid-adj.) MA Low 276 (0) 2.1 (1.8–2.5) 519 (0) 5.3 (4.9–5.7) 0.41 (0.34–0.48)
PCB99 (ng/g, serum) MA Low 275 (0) 0.013 (0.011–0.015) 517 (0) 0.026 (0.023–0.029) 0.51 (0.43–0.60)
PCB99 (ng/g, serum, lipid-adj.) MA Low 275 (0) 2.2 (1.9–2.5) 517 (0) 4.2 (3.8–4.7) 0.52 (0.44–0.61)
PCB118 (ng/g, serum) MA Low 275 (0) 0.019 (0.016–0.023) 516 (0) 0.037 (0.033–0.042) 0.51 (0.40–0.64)
PCB118 (ng/g, serum, lipid-adj.) MA Low 275 (0) 3.2 (2.7–3.7) 516 (0) 6.1 (5.5–6.8) 0.52 (0.41–0.65)
PCB138 & 158 (ng/g, serum) MA Low 276 (0) 0.037 (0.032–0.044) 517 (0) 0.097 (0.086–0.11) 0.38 (0.31–0.47)
PCB138 & 158 (ng/g, serum,
lipid-adj.)
MA High 128 (0) 8.8 (7.3–11) 517 (0) 16 (14–18) 0.55 (0.44–0.69)
PCB138 & 158 (ng/g, serum,
lipid-adj.)
MA Low 276 (0) 6.2 (5.3–7.2) 517 (0) 16 (14–18) 0.39 (0.32–0.48)
PCB146 (ng/g, serum, lipid-adj.) MA High 127 (4) 1.1 (0.87–1.4) 519 (4) 2.3 (2.0–2.5) 0.48 (0.37–0.63)
PCB146 (ng/g, serum) MA Low 275 (8) 0.0052 (0.0044–0.0061) 519 (4) 0.014 (0.012–0.016) 0.37 (0.3–0.46)
PCB146 (ng/g, serum, lipid-adj.) MA Low 275 (8) 0.86 (0.73–1.0) 519 (4) 2.3 (2.0–2.5) 0.38 (0.31–0.47)
PCB153 (ng/g, serum, lipid-adj.) MA High 127 (0) 11 (9.1–13) 519 (0) 22 (20–24) 0.50 (0.41–0.63)
PCB153 (ng/g, serum) MA Low 275 (0) 0.046 (0.038–0.055) 519 (0) 0.13 (0.12–0.15) 0.35 (0.28–0.43)
PCB153 (ng/g, serum, lipid-adj.) MA Low 275 (0) 7.7 (6.4–9.1) 519 (0) 22 (20–24) 0.36 (0.29–0.44)
PCB156 (ng/g, serum) MA Low 273 (81) 0.0034 (0.002–0.0056) 515 (43) 0.019 (0.017–0.021) 0.18 (0.11–0.31)
PCB156 (ng/g, serum, lipid-adj.) MA Low 273 (81) 0.58 (0.36–0.93) 515 (43) 3.1 (2.7–3.4) 0.19 (0.11–0.31)
PCB170 (ng/g, serum, lipid-adj.) MA High 127 (6) 3.2 (2.6–4.0) 517 (5) 6.2 (5.8–6.7) 0.52 (0.41–0.65)
PCB170 (ng/g, serum) MA Low 273 (17) 0.011 (0.0091–0.014) 517 (5) 0.038 (0.035–0.041) 0.30 (0.23–0.39)
PCB170 (ng/g, serum, lipid-adj.) MA Low 273 (17) 1.9 (1.5–2.4) 517 (5) 6.2 (5.8-6.7) 0.31 (0.24–0.39)
PCB177 (ng/g, serum) MA Low 273 (92) 0.0024 (0.0018–0.0033) 515 (67) 0.0069 (0.0062–0.0077) 0.35 (0.26–0.47)
PCB177 (ng/g, serum, lipid-adj.) MA Low 273 (92) 0.41 (0.31–0.55) 515 (67) 1.1 (1.0–1.3) 0.36 (0.27–0.49)
PCB180 (ng/g, serum, lipid-adj.) MA High 128 (1) 8.2 (6.3–11) 517 (2) 17 (16–19) 0.48 (0.36–0.62)
PCB180 (ng/g, serum) MA Low 276 (4) 0.031 (0.024–0.039) 517 (2) 0.11 (0.096–0.12) 0.29 (0.23–0.38)
PCB180 (ng/g, serum, lipid-adj.) MA Low 276 (4) 5.2 (4.1–6.4) 517 (2) 17 (16–19) 0.30 (0.24–0.38)
PCB183 (ng/g, serum) MA Low 274 (45) 0.0036 (0.0029–0.0044) 518 (35) 0.0097 (0.0089–0.011) 0.37 (0.30–0.46)
PCB183 (ng/g, serum, lipid-adj.) MA Low 274 (45) 0.60 (0.50–0.72) 518 (35) 1.6 (1.5–1.7) 0.38 (0.31–0.46)















Table 2 Chemicals with higher biomarker levels in the reference subgroup (GMR < 1 at 5% joint significance level) (Co inued)
PCB187 (ng/g, serum, lipid-adj.) MA Low 275 (8) 1.6 (1.2–2.0) 519 4.5 (4.1–5.0) 0.35 (0.27–0.45)
PCB194 (ng/g, serum) MA Low 265 (98) 0.0029 (0.0016–0.0052) 508 ( ) 0.02 (0.018–0.023) 0.14 (0.079–0.25)
PCB194 (ng/g, serum, lipid-adj.) MA Low 265 (98) 0.50 (0.29–0.87) 508 ( ) 3.4 (3.1–3.7) 0.15 (0.085–0.26)
PCB196 & 203 (ng/g, serum) MA Low 274 (63) 0.0038 (0.0025–0.0058) 517 ( ) 0.019 (0.017–0.021) 0.20 (0.13–0.31)
PCB196 & 203 (ng/g, serum,
lipid-adj.)
MA Low 274 (63) 0.65 (0.44–0.97) 517 ( ) 3.1 (2.8–3.4) 0.21 (0.14–0.32)
PCB199 (ng/g, serum) MA Low 272 (69) 0.0036 (0.0023–0.0057) 509 ( ) 0.021 (0.018–0.023) 0.18 (0.11–0.29)
PCB199 (ng/g, serum, lipid-adj.) MA Low 272 (69) 0.62 (0.39–0.96) 509 ( ) 3.4 (3.0–3.8) 0.18 (0.11–0.29)
PCB206 (ng/g, serum) MA Low 271 (41) 0.0041 (0.0029–0.0057) 513 ( ) 0.015 (0.013–0.017) 0.27 (0.19–0.39)
PCB206 (ng/g, serum, lipid-adj.) MA Low 271 (41) 0.69 (0.50–0.95) 513 ( ) 2.4 (2.2–2.7) 0.28 (0.20–0.39)
PCB209 (ng/g, serum) MA Low 269 (32) 0.0034 (0.0026–0.0044) 510 ( ) 0.0092 (0.0078–0.011) 0.37 (0.27–0.51)
PCB209 (ng/g, serum, lipid-adj.) MA Low 269 (32) 0.57 (0.44–0.73) 510 ( ) 1.5 (1.3–1.7) 0.38 (0.28–0.51)
Metals (2007–2008) BARIUM (ug/g, urine,
creatinine-adj.)
NHB High 284 (2) 0.87 (0.79–0.96) 581 1.9 (1.7–2.1) 0.46 (0.40–0.54)
BARIUM (ug/g, urine,
creatinine-adj.)
NHB Low 264 (6) 0.84 (0.72–0.99) 581 1.9 (1.7–2.1) 0.45 (0.36–0.56)
CESIUM (ug/g, urine,
creatinine-adj.)
NHB High 284 (0) 3.6 (3.4–3.9) 581 4.8 (4.6–5.1) 0.75 (0.68–0.83)
CESIUM (ug/g, urine,
creatinine-adj.)
NHB Low 264 (0) 3.2 (3.0–3.4) 581 4.8 (4.6–5.1) 0.66 (0.59–0.73)
COBALT (ug/g, urine,
creatinine-adj.)
NHB High 284 (0) 0.30 (0.28–0.32) 581 0.39 (0.37–0.41) 0.76 (0.71–0.82)
MERCURY, TOTAL (ug/L, blood) MA Low 1,056 (314) 0.53 (0.47–0.59) 1,819 ( 5) 0.82 (0.73–0.93) 0.65 (0.55–0.76)





NHB High 233 (0) 2.1 (1.7–2.5) 673 3.7 (3.3–4.1) 0.57 (0.46–0.70)
PERCHLORATE (ug/g, urine,
creatinine-adj.)
NHB Low 365 (0) 2.5 (2.2–2.8) 673 3.7 (3.3–4.1) 0.67 (0.61–0.73)
PFCs (2007–2008) PERFLUOROOCTANE SULFONIC ACID
(ug/L, blood)
MA Low 234 (0) 9.6 (8.4–11) 500 14 (13–16) 0.67 (0.57–0.78)
PERFLUOROOCTANOIC ACID
(ug/L, blood)
MA Low 234 (0) 3.3 (3.0–3.6) 500 4.5 (4.3–4.8) 0.73 (0.66–0.80)
PERFLUOROOCTANOIC ACID
(ug/L, blood)






































Table 2 Chemicals with higher biomarker levels in the reference subgroup (GMR < 1 at 5% joint significance level) (Continued)
Phenols (2007–2008) BENZOPHENONE-3 (ng/mL, urine) NHB High 258 (18) 8.1 (6.1–11) 588 (20) 30 (18–49) 0.27 (0.16–0.45)
BENZOPHENONE-3
(ng/g, urine, creatinine-adj.)
NHB High 258 (18) 6.0 (4.6–7.6) 588 (20) 31 (19–52) 0.19 (0.11–0.32)
Notes: (a) Biomarkers were assigned to chemical groups on the basis of chemical consistency and groupings from the NHANES laboratory files. Biomonitoring data for the results in the table come from NHANES 2007–2008 for
metals, PFCs, and phenols; and from NHANES 2003–2004 for halogenated aromatics and perchlorate. (b) MA – Mexican American, NHB – non-Hispanic black, NHW – non-Hispanic white; Low income corresponds to family PIR < 2,
High income corresponds to family PIR ≥ 2 (PIR is the poverty income ratio). (c) The number of observations is unweighted. The number of non-detects (ND) is reported in parentheses. (d) The point estimate, followed by the range
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http://www.ehjournal.net/content/12/1/114among Mexican Americans. CDC reported that Mexican
Americans had the highest levels in NHANES 1999–2004,
with the 2003–2004 GM dropping >30% from earlier cy-
cles, a possible result of Mexico’s 2000 DDT phase-out and
the high proportion of new immigrants among Mexican
Americans [37]. A study of low-income, pregnant Mexican
American women in California found higher p,p’-DDE as-
sociated with time spent living outside the United States
and with birthplace in areas of Mexico with recent DDT
use [38]. We further examined the NHANES 2003–2004
organochlorine pesticide data and found a higher propor-
tion of born-in-Mexico (versus born-in-U.S.) participants
in the Mexican American/Low Income subgroup (0.59;
95% CI 0.47–0.72) versus the High Income subgroup (0.37;
95% CI 0.27–0.47), which may help explain our finding.
Parabens
Similar to the NHANES 2005–2006 findings of Calafat
et al. [39], we observed higher urinary methyl and propyl
paraben concentrations among high-income, non-Hispanic
blacks in NHANES 2007–2008. We also found methyl
paraben to be elevated among low-income, non-Hispanic
blacks. The methyl paraben result for high-income blacks
was not sensitive to whether the measurements were
creatinine-corrected, consistent with descriptive statistics
reported by CDC for non-Hispanic blacks [9].
Phthalates
We found higher diethyl phthalate (urinary mono-ethyl
phthalate) and dibutyl phthalate (urinary mono-isobutyl
and mono-n-butyl phthalate) metabolites in low-income
minority subgroups, with higher mono-ethyl phthalate
also in high-income, non-Hispanic blacks. Race/ethnicity
differences in exposure to these phthalate metabolites
were previously documented [40], and evidence regarding
income-related differences is conflicting. Higher exposures
to summed urinary metabolites of low-molecular-weight
phthalates were reported for minority and for lower-
income children (ages 6–19) [41]; inverse associations
between dibutyl phthalate metabolites and income
(controlling for race) were also found in NHANES 2001–
2010 [10]. Controlling for SES (an index including income,
education, and food security), elevated urinary mono-ethyl
phthalate and dibutyl phthalate metabolites were found in
minority reproductive-age women, but SES itself was insig-
nificant in the presence of minority status controls [42].
Sb and Tl
We found higher urinary Sb (uncorrected) in non-
Hispanic blacks (low and high income) and higher urin-
ary Tl (uncorrected) in low-income non-Hispanic blacks.
Richter et al. [43] found higher urinary Sb in NHANES
1999–2004 non-smokers with environmental tobacco
smoke exposure compared to non-smokers with no suchexposure, but no difference by race/ethnicity. In contrast,
they found lower urinary Tl in smokers versus non-
smokers. Tyrrell et al. reported negative associations be-
tween Sb and income (controlling for race) [10], but no
race-related differences.
Dichlorophenols
We found elevated 2,4– and 2,5-dichlorophenol (DCP)
in non-Hispanic blacks (low and high income). Evidence
of EJ concerns exists for the 2,5-DCP parent compound
(1,4–dichlorobenzene), with elevated blood levels found
in Mexican Americans and non-Hispanic blacks [44,45].
Urinary 2,5–DCP was found to be significantly lower in
non-Hispanic white girls compared to non-Hispanic black
girls participating in a breast cancer study [46].
Chemicals with higher concentrations in the
reference subgroup
The screening method identified 25 chemicals with sig-
nificantly higher biomarker levels in high-income, non-
Hispanic whites (Table 2), with previously published
evidence of disparity for most. We found lower serum
levels of 17 PCB congeners in Mexican Americans than in
high-income, non-Hispanic whites, consistent with other
NHANES studies [47,48] and regional U.S. studies [49].
All of the congeners with significant differences, except
PCB118 and PCB156, were non-dioxin like, and results
were not sensitive to the lipid adjustment. We found lower
total blood mercury (Hg) in low-income, non-Hispanic
whites and Mexican Americans, consistent with studies
reporting lower Hg levels among Mexican Americans
[50,51] and inverse associations between Hg and income
[10]. We found lower urinary perchlorate in non-Hispanic
blacks (low- and high-income) versus high-income, non-
Hispanic whites in NHANES 2003–2004, similar to
Blount et al.’s [52] NHANES 2001–2002 finding for men.
We found lower serum perfluoroctanoic acid (PFOA) in
the low-income minority subgroups and lower perfluor-
ooctane sulfonic acid (PFOS) among low-income Mexican
Americans, consistent with NHANES 1999–2008 findings
of lower PFOA and PFOS in Mexican Americans and
lower PFOA in blacks [53], and with NHANES 2003–
2008 findings of negative associations between income
and PFOA and PFOS levels [10,54]. Lower urinary
benzophenone-3 was found in blacks in NHANES 2003–
2004 [55] and higher-income individuals in NHANES
2003–2010 [10], similar to our NHANES 2007–2008 find-
ing in high-income, non-Hispanic blacks. Last, we found
lower concentrations of urinary barium (Ba) and cesium
(Cs) in non-Hispanic blacks (low- and high-income),
and lower concentrations of cobalt (Co) in high-income,
non-Hispanic blacks, compared to high-income, non-
Hispanic whites. Although there is evidence of inverse as-
sociations between Cs and income (controlling for race)
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lished evidence of race/ethnicity-related disparities in
these metals.
Discussion
Utility and performance of the screening method
This analysis provides a formal method to screen for
exposure disparities in NHANES environmental bio-
monitoring data across race/ethnicity and income. The
screening method identified differential exposure at the
mean for 59 of the 204 (29%) biomarkers examined, with
some instances of potential EJ concern and others where
the reference subgroup (non-Hispanic white/High Income)
had higher exposures. Using the published literature as a
qualitative validation tool, the method correctly identified
five chemicals/chemical classes with published evidence of
higher biomarker levels in low-income or minority groups
(cotinine, lead, DDE, parabens, and phthalates), and five
chemicals/chemical classes with higher levels in high-
income whites (PCBs, Hg, perchlorate, PFOA/PFOS, and
benzophenone-3). It also found differential exposures for
seven chemicals (2,4− and 2,5−DCP, Tl, Sb, Ba, Co, Cs)
for which no published evidence of differences by race/
ethnicity or income exists. The screening method is an ap-
proach that users of NHANES biomonitoring data could
employ to obtain new and robust insights into the nexus
between chemical exposures and diverse populations.
Public health relevance of initial screening results
The main objective of this work was to develop an EJ
screening method for the NHANES biomarker data.
Because we used only one cycle of NHANES data to de-
velop the method (the most recently available per chem-
ical), our actual screening results should be viewed as
preliminary. Furthermore, there are many other poten-
tially important race/ethnicity disparities that we were
unable to evaluate because the NHANES dataset contains
sufficient sample sizes to reliably analyze only Mexican
American, non-Hispanic white, and non-Hispanic black
subgroups [16]. Nonetheless, we did find evidence, sup-
ported by the published literature, of EJ concern in
biomarker levels of cotinine, Pb, DDE, parabens, and
phthalates. While smoking is not typically viewed as an EJ
issue, higher cotinine levels in low-income, non-Hispanic
whites and blacks indicate higher smoking-related health
burdens. This merits further investigation into factors
driving higher smoking rates and secondhand smoke ex-
posures, so that effective prevention strategies can be de-
veloped. We also found higher Pb in low-income blacks.
An extensive literature points to indoor/housing-related
factors (e.g., house dust, tobacco smoke, housing age/
condition/geographic location) as important drivers of
Pb exposure in the United States, with dietary, toxico-
kinetic, and genetic factors influencing biomarkerdifferences [56]. With research demonstrating adverse ef-
fects at ever-decreasing Pb levels, including associations
with cardiovascular outcomes [35,57], the public health
impacts of Pb disparities are potentially large.
We found higher DDE levels among Mexican Americans.
Since prenatal p,p’-DDE exposure is associated with ad-
verse neurodevelopmental outcomes [37], the public
health impacts of this disparity could be significant. We
found higher paraben levels among high-income, non-
Hispanic blacks. Parabens are antimicrobial preservatives
with weak estrogenic properties used in cosmetics, phar-
maceuticals, and some processed foods [58]. Exposure dif-
ferences are likely due to product use or diet, although
indoor air and house dust may be important [59]. We
found certain phthalate metabolites higher in low-income
minority subgroups and high-income, non-Hispanic blacks.
Phthalates are ubiquitous plasticizers, with diet and con-
sumer products considered important exposure sources
[6]. Human health implications of phthalate exposure is an
active research area, with some suggestion of endocrine-
disrupting effects [41,60].
We also found previously undocumented evidence of
disparities in biomarker levels of Sb, Tl, and 2,4- and
2,5-DCP for non-Hispanic blacks. Sb and Tl are toxic
metals used in a range of industrial processes. Anthropo-
genic sources include power plants (both), traffic emis-
sions and brake dust (Sb), tobacco smoke (both), mining
operations (Sb), cement factories and smelters (Tl), and
waste sites (both) [61]. People are exposed to Sb primar-
ily through food and to Tl through industrial processes
[6]. Human health effects from Sb or Tl at low environ-
mental doses are unknown [6]. 2,4–DCP is a metabolite
of several herbicides, organophosphate, and organochlor-
ine pesticides (including other chlorophenols), while 2,5–
DCP is a metabolite of several organochlorine pesticides
(including 1,4–dichlorobenzene, a deodorizer and moth
repellent) [6,62,63]. They can also be used in water chlor-
ination [64]. In terms of potential health effects, food
allergy sensitization was more common in NHANES
2005–2006 participants with levels of urinary 2,4– and
2,5–DCP above the 75th percentile [64], and lower age of
menarche was associated with 2,5–DCP and aggregated
2,4– and 2,5–DCP in NHANES 2003–2008 female partici-
pants 12–16 years of age [65].
We also found evidence, supported by the literature,
of lower levels of certain chemicals in low-income and
minority subgroups versus high-income non-Hispanic
whites. PCB levels were lower in Mexican Americans,
most likely due to differences in diet, the younger aver-
age age of Mexican Americans (34 years; 95% CI 31–36)
versus whites (44 years; 95% CI 43–45), and the large
fraction (0.56; 95% CI 0.42–0.66) of Mexican-born par-
ticipants (who have been shown to have lower levels of
PCB153 than U.S.-born Mexican Americans [48]) in the
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2004 data. Hg levels were lower in low-income non-
Hispanic whites and Mexican Americans, consistent with
studies linking higher income with higher Hg intake
through fish consumption [6,10,50,51]. We found lower
perchlorate in non-Hispanic blacks, and lower PFOA and
PFOS in the low-income minority subgroups. Perchlorate
is a thyrotoxic natural and anthropogenic contaminant
found in food (vegetables, milk) and drinking water,
depending on location. PFOA and PFOS (phased out
of U.S. production in 2002) are persistent manmade
chemicals with a range of applications (e.g., waterproofing,
protective coatings) and suspected health effects. Levels of
benzophenone-3, a suspected endocrine-disrupting sun-
screen used in cosmetics, sunscreen, and food packaging,
were lower in high-income non-Hispanic blacks.
Last, we found previously undocumented evidence of
lower Ba, Cs, and Co in non-Hispanic blacks compared
to high-income non-Hispanic whites. Ba is a naturally
occurring metal in food and drinking water, with indus-
trial and medical applications [66]; disparities could indi-
cate differences in diet, drinking water, or possibly access
to colorectal screening. Americans are exposed to both
stable (naturally occurring, and from forest fires, coal,
and waste combustion; not considered a public health
concern) and radioactive (from nuclear power plants, ac-
cidents, or weapon explosions) Cs isotopes through food,
drinking water, and air; thus, disparities are likely due to
differences in diet and geography [67]. Americans are
also exposed to stable and radioactive Co isotopes through
food, water, and air. Since Co is an essential micronutrient,
exposure to typical environmental levels of stable Co
is not considered harmful [68]. Urinary Cs and Co meas-
urement methods do not distinguish between stable and
radioactive species.
Limitations
We were unable to analyze 50% of the available
NHANES biomarkers for disparity because the LOD
censoring was often too high to yield a valid GM es-
timate. In the VOC chemical group this was true for
33 out of 39 biomarkers. However, the lack of informa-
tion about race/ethnicity and income differences for
these biomarkers should not be interpreted as the ab-
sence of such differences. With improvements in the
sensitivity of analytical methods, LOD censoring should
become less of a limitation.
For 71% of biomarkers, none of the estimated GMRs was
significantly different from 1. This was the case for all 20
PAH biomarkers. The lack of significant findings for these
biomarkers may be a consequence of insufficient statistical
power; in other words, race/ethnicity and income differences
may exist, but we were unable to detect them. Pooling
biomarker data across several NHANES cycles would haveincreased sample sizes and, potentially, the precision
of our estimates, but would not have altered our conclu-
sions about the validity of the screening method itself.
To control the FWER in the family of 795 screening
tests performed, we used the Holm-Bonferroni proced-
ure. While this procedure was shown to be more power-
ful than the Bonferroni correction [30], it does not
permit construction of simultaneous confidence inter-
vals. Therefore, the confidence intervals for the GMRs
reported in Table 1 and Table 2 are not adjusted for mul-
tiple comparisons. There are several other FWER control
methods that have higher statistical power compared to
the Holm-Bonferroni procedure. Adaptive Bonferroni
methods require knowledge of (or assumptions about)
data dependencies [69,70]. However, we could not infer
the correlation structure across all NHANES biomarkers,
because not all measurements were collected from the
same individuals. Permutation-based methods, such as the
MaxT test procedure [71], accommodate arbitrary de-
pendency structures. However, they rely on the assump-
tion that individual-level observations are exchangeable,
which is difficult to justify for the complex survey data.
Further, the MaxT procedure did not considerably outper-
form the Holm-Bonferroni procedure in terms of statis-
tical power in some simulation experiments [72,73]. Thus,
we used an approach to control the FWER that we felt
was most appropriate for these data.
There are other types of disparity that we were unable
to capture by screening at the means. Higher variability
in a given biomarker concentration in a target subgroup
(versus the reference subgroup) implies that, even with
similar GMs, extreme values may be more frequent in
that subgroup. We explored this in a complementary,
upper-tail-oriented screening that defined extreme con-
centrations (as ≥95th percentile) and found few significant
results. This was likely a consequence of the additional
sampling uncertainty in the test statistic estimator used
for this upper-tail screening, because the 95th percentile
value had to be estimated from the data. When juxtaposed
with results from screening at the mean, fewer significant
findings at the upper tail could be misinterpreted as a
relative absence of the upper-tail disparity. Therefore, we
did not report the results of this analysis.
Ideally, an upper-tail screening analysis would be based on
externally defined, non-occupational health-based thresh-
olds, such as biomonitoring equivalents (BEs). A BE is a
biological concentration of a chemical (or its metabolites)
reflecting an existing health-based exposure guidance value,
such as a reference dose [74]. BEs have been established for
approximately 80 chemicals [74], but many NHANES
chemicals still lack them. Additionally, grouping biomarkers
of chemicals with shared toxicity pathways could help
capture toxicity-relevant race/ethnicity and income differ-
ences in cumulative exposures.
Belova et al. Environmental Health 2013, 12:114 Page 14 of 17
http://www.ehjournal.net/content/12/1/114Education and occupation are other important SES di-
mensions we did not examine explicitly because we ana-
lyzed biomarker data for all available ages, where these are
not always applicable. For adults, education is typically cor-
related with income; thus, our income-related findings
could be viewed more broadly as representing income- and
education-related patterns. However, another study found
that, while education and income were correlated, they
were not associated with bisphenol A and PFC biomonitor-
ing levels in the same way [54]. Some of the NHANES bio-
marker concentrations may have reflected occupational
exposures, which may occur more frequently in low-
income subpopulations (and for some race/ethnicity
subpopulations). However, if one assumes that worker
exposures are higher than those of the general population,
then our focus on disparities at the mean likely helped
dampen the influence of occupation on our screening find-
ings. Future detailed studies should consider occupation as
an important potential source of variability in biomarker
data and possible explanation for observed disparities.
Unfortunately, the NHANES occupational codes typ-
ically do not contain the detail needed to identify
specific high-exposure industries or job tasks.
Our screening analysis did not capture possible “hotspot”
effects, such as elevated biomarker levels in communities
near contaminant sources. Community-level occurrences of
elevated concentrations are either diluted or missed
altogether if these communities are not included in the
NHANES sample. Although the NHANES geographic iden-
tifiers are available through special arrangement, accessing
them requires additional time and resources; only a few
researchers to date have attempted this [75]. Further, having
the geographic identifiers alone cannot help elucidate
whether biomarker disparities are due to environmental
contamination without the corresponding local environ-
mental data (e.g., air, drinking water, soil, house dust, food
measurements), which NHANES generally lacks. For this,
we need more detailed studies, such as those described in
the introduction [3,4], matching environmental, geographic,
and SES data.
Interpreting urinary biomarker levels when results differ
by creatinine correction can be challenging. Because non-
Hispanic blacks have higher creatinine excretion [15],
GMRs that were not significant for creatinine-corrected
concentration (but significant for uncorrected concentra-
tion) may reflect creatinine excretion rather than exposure
differences. However, creatinine also varies by several other
factors (e.g., age, sex, renal function, lean muscle mass, red
meat consumption [15]). We did not account for these
factors in our analysis, clouding the interpretation of differ-
ent results for urinary concentrations expressed in different
units. Other approaches to account for urine dilution (e.g.,
by specific gravity [76]) may be preferable when 24-hour
samples are unavailable.Other limitations of our analysis relate to the inherent
characteristics of a screening-level exploration versus a
detailed EJ analysis of the NHANES biomonitoring data.
Several studies focusing on clusters of a few chemicals
have demonstrated the value of individual-level covariates
—such as age, sex, education, occupation, smoking, diet,
and body mass index—in explaining biomarker differences
across EJ subgroups. However, the set of important covari-
ates could also include genetic/epigenetic characteristics
that influence toxicokinetics, resulting in different in-
ternal doses for individuals with the same external
exposures [7,8]. Although NHANES is a rich source of
individual-level information, it does not provide genetic/
epigenetic data.
This screening analysis focused on identifying race/
ethnicity and income differences in mean concentrations
for a large number of the NHANES biomarkers, rather
than on interpreting these differences. Making inferences
about factors that can account for these observed differ-
ences should be assisted by a correctly specified model of
individual-level internal exposures that includes all
relevant covariates. It was not feasible to build a compre-
hensive model for each biomarker in our study. Further,
including just a few covariates (e.g., age and sex) was likely
to produce models subject to omitted-variable bias and,
consequently, faulty inferences about the relative import-
ance of these covariates in explaining the mean differences
in exposure across subgroups. Therefore, we focused on a
simpler screening that could potentially be useful for iden-
tifying candidate chemicals for more detailed EJ-oriented
assessments.
Conclusions
This analysis explored differences in exposure to environ-
mental chemicals (using biomarkers) across the dimen-
sions of race/ethnicity and income in the United States.
Many findings were consistent with previous studies,
while some findings were new. Screening analyses of this
type can be useful in identifying chemicals for focused
study. Researchers wishing to extend our analyses might
consider upper-tail screening using BE-based thresholds,
exploring patterns in cumulative exposure (by grouping
biomarkers with shared toxicity), or examining effects of
creatinine correction and lipid adjustment on findings for
certain chemical groups. Incorporating additional years of
NHANES data as they become available could help iden-
tify persistent disparities requiring public health attention.Additional file
Additional file 1: A Method to screen U.S. environmental
biomonitoring data for race/ethnicity and income-related disparity.
A description of chemical groups and their corresponding NHANES
laboratory files and an overview of significant GMR findings.
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